Vaxcyte, Inc. (NASDAQ:PCVX) CEO Sells $928,800.00 in Stock

Vaxcyte, Inc. (NASDAQ:PCVX) CEO Grant Pickering sold 15,000 shares of Vaxcyte stock in a transaction that occurred on Tuesday, April 23rd. The stock was sold at an average price of $61.92, for a total value of $928,800.00. Following the completion of the transaction, the chief executive officer now owns 477,847 shares of the company’s stock, valued at approximately $29,588,286.24. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Grant Pickering also recently made the following trade(s):

• On Monday, March 25th, Grant Pickering sold 15,000 shares of Vaxcyte stock. The stock was sold at an average price of $66.93, for a total value of $1,003,950.00.
• On Friday, March 1st, Grant Pickering sold 2,616 shares of Vaxcyte stock. The shares were sold at an average price of $73.70, for a total value of $192,799.20.
• On Thursday, February 1st, Grant Pickering sold 2,616 shares of Vaxcyte stock. The shares were sold at an average price of $73.91, for a total value of $193,348.56.
• On Monday, January 29th, Grant Pickering sold 30,000 shares of Vaxcyte stock. The shares were sold at an average price of $66.03, for a total value of $1,980,900.00.

Vaxcyte Trading Up 1.1 %

PCVX opened at $60.72 on Friday. The firm has a market cap of $6.60 billion, a price-to-earnings ratio of -14.70 and a beta of 0.89. Vaxcyte, Inc. has a 12 month low of $41.57 and a 12 month high of $82.04. The stock has a fifty day moving average price of $67.96 and a 200-day moving average price of $61.44.

Vaxcyte (NASDAQ:PCVX) last released its quarterly earnings results on Tuesday, February 27th. The company reported ($1.82) EPS for the quarter, missing the consensus estimate of ($0.89) by ($0.93). During the same period in the previous year, the company earned ($0.73) earnings per share. On average, equities research analysts forecast that Vaxcyte, Inc. will post -4.18 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on PCVX. Bank of America boosted their price objective on Vaxcyte from $67.00 to $80.00 and gave the company a “buy” rating in a report on Tuesday, January 2nd. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Vaxcyte in a research report on Friday, January 12th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $95.00 target price on shares of Vaxcyte in a research report on Wednesday, April 10th. Four investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $78.50.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Xponance Inc. grew its stake in Vaxcyte by 3.0% during the 4th quarter. Xponance Inc. now owns 5,672 shares of the company’s stock worth $356,000 after buying an additional 163 shares during the last quarter. Ellsworth Advisors LLC grew its stake in Vaxcyte by 2.6% during the 4th quarter. Ellsworth Advisors LLC now owns 8,060 shares of the company’s stock valued at $506,000 after purchasing an additional 207 shares during the last quarter. Parallel Advisors LLC grew its stake in Vaxcyte by 155.3% during the 4th quarter. Parallel Advisors LLC now owns 411 shares of the company’s stock valued at $26,000 after purchasing an additional 250 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its stake in Vaxcyte by 0.6% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 51,136 shares of the company’s stock valued at $3,211,000 after purchasing an additional 296 shares during the last quarter. Finally, Principal Financial Group Inc. grew its stake in Vaxcyte by 1.7% during the 4th quarter. Principal Financial Group Inc. now owns 22,008 shares of the company’s stock valued at $1,382,000 after purchasing an additional 376 shares during the last quarter. 96.78% of the stock is currently owned by hedge funds and other institutional investors.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.